Publications by authors named "P Padilla-Iserte"
Article Synopsis
- Sentinel lymph node (SLN) mapping in epithelial ovarian cancer may lower risks from lymphadenectomy while still providing reliable diagnostic results; ongoing research aims to evaluate its effectiveness.
- A systematic review of four studies involving 239 patients found SLN detection rates of 59.5% for pelvic and 64.4% for para-aortic regions, with technetium-99 showing better detection rates compared to indocyanine green.
- Diagnostic accuracy for identifying lymph node metastasis was high, reaching 100% in the pelvic field and 98.1% for the para-aortic field, suggesting SLN mapping could be a valuable tool in this context.
Background: There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined.
View Article and Find Full Text PDFBackground: The incidence of anastomotic leak after colorectal anastomosis in ovarian cancer has been reported to be much lower than that in colorectal cancer patients. Regarding the use of protective manoeuvres (diverting ileostomy) as suggested by clinical guidelines, the goal should be the implementation of a restrictive stoma policy for ovarian cancer patients, given the low rate of anastomotic leakage in this population.
Material And Methods: Patients who underwent cytoreduction surgery in a single centre (University Hospital La Fe, Valencia Spain) due to ovarian cancer between January 2010 and June 2023 were classified according to two groups: a non-restrictive stoma policy group (Group A) and a restrictive stoma policy group (Group B).
Introduction: The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
Materials And Methods: We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]).